No Detail Found!

Miltefosine or Antimonials: An in vitro Evaluation of Sensitivity against Leishmania tropica

Author(s)
Qaisar Jamal Institute of Zoological Sciences, University of Peshawar, Peshawar 25120, Pakistan
Rabia Bari Institute of Zoological Sciences, University of Peshawar, Peshawar 25120, Pakistan
Safia Bibi Institute of Zoological Sciences, University of Peshawar, Peshawar 25120, Pakistan
Khalid Saleem Vector Control, District Khyber, Department of Health, KP 25000, Pakistan
Moeen Uddin Institute of Zoological Sciences, University of Peshawar, Peshawar 25120, Pakistan
Abstract
Antimony containing agents, meglumine antimoniate and sodium stibogluconate, are the first line of chemotherapy against cutaneous leishmaniasis in Pakistan. A comparison of the efficacy of these antimonials and miltefosine, the only oral therapy for leishmanisis was assessed in vitro. Eight different isolates of L. tropica were exposed to 4 different concentrations of the drugs for 48 hours under the standard conditions for L. tropica cultivation. At the end of exposure time, viability of the parasites was checked through XTT colorimetric assay. The efficacy of miltefosine stood matchless as compared to pentostam and glucantime; standard antimonial drugs. The average activity of miltefosine differed Significantly than the other standard drugs (miltefosine vs Glucantime p=0.003; miltefosine vs pentostam p=0.0045; glucantime vs pentostam p=0.006). The mean IC50 values of mltefosine, glucantime and pentostam were respectively 1.476 ± 1.088µg/mL, 6.746 ± 2.438µg/mL and 85.970 ± 82.201µg/mL. Significant differences were noted in IC50 of the drugs (miltefosine vs glucantime p=0.0003; miltefosine vs pentostam p=0.0242; glucantime vs pentostam p=0.0501). This study showed miltefosine as a more suitable option for treating L. tropica. This might be of practical importance in areas with higher prevalence of resistance to antimonials.
Publication Details
Page(s) 1-10
DOI DOI not available
Published Journal: The Sciencetech, Volume: 6, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
in vitro Sensitivity, Antmonials, Leishmania tropica, Miltefosine
References
Alcântara L. M.,Ferreira T. C. S.,Gadelha F. R.,Miguel D. C. .2018 .Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis. Internation Journal of Parasitology and Drug Resistance, 8(3) : 430-439.
Bhusal C. K.,Sinha S.,Kaur D.,Sehgal R. .2025 .Unravelling drug resistance in leishmaniasis: genomic adaptations and emerging therapies. Frontiers in Molecular Biosciences, 12 : 1573618.
Bilgic-Temel A.,Murrell D. F.,Uzun S. .2019 .Cutaneous leishmaniasis: A neglected disfiguring disease for women. Internation Journal of Womens Dermatology, 5(3) : 158-165.
Buchelt M.,Valero T.,Kinaciyan T.,Walochnik J.,Egg M.,Szelenyi A.,Langer S.,Handisurya A. .2025 .Off-label treatment with miltefosine for complex, pediatric Old World cutaneous leishmaniasis. JAAD Case Reports, 64 : 26-29.
Cecílio P.,Silva A.,Oliveira F. .2022 .Sand flies: Basic information on the vectors of leishmaniasis and their interactions with Leishmania parasites. Communications Biology, 5(1) : 305.
Levatti C. R.,Boité E. V. C.,Lamounier M. C.,Alvar D.,Cupolillo J.,Costa E.,Rode C. H. N.,Uliana J.,S. R. B. J. .2021 .In vitro susceptibility to miltefosine of Leishmania infantum (syn. L. chagasi) isolates from different geographical areas in Brazil. , 9(6) : 1228.
Ginouvès M.,Simon S.,Nacher M.,Demar M.,Carme B.,Couppié P.,Prévot G. .2017 .In Vitro sensitivity of cutaneous Leishmania promastigote isolates circulating in French Guiana to a set of drugs. Americal Journal of Tropical Medicine and Hygiene, 96(5) : 1143-1150.
Goswami R. P.,Rahman M.,Das S.,Tripathi S. K.,Goswami R. P. .2020 .Combination therapy against indian visceral leishmaniasis with liposomal amphotericin B (FungisomeTM) and short-course miltefosine in comparison to miltefosine monotherapy. Americal Journal of Tropical Medicine and Hygiene, 103(1) : 308-314.
Gupta S.,Nishi S. .2011 .Visceral leishmaniasis: Experimental models for drug discovery. Indian Journal of Medical Research, 133(1) : 27-39.
Jafari R.,Najafzadeh N.,Sedaghat M.,Parvizi P. .2013 .Molecular characterization of sandflies and Leishmania detection in main vector of zoonotic cutaneous leishmaniasis in Abarkouh district of Yazd province. Iran. Asian Pacific Journal of Tropical Medicine, : 792-797.
Khademvatan S.,Gharavi M. J.,Saki J. .2011 .Miltefosine induces metacaspase and PARP genes expression in Leishmania infantum. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 15(5) : 442-448.
Khan S.,Kakakhel S. I.,Khan Amir,Shams U.,Shams H.,Rehman S.,Hamza S. .2024 .Comparison of miltefosine with glucantime for the treatment of cutaneous leishmaniasis. Pakistan Journal of Health Sciences, 5(12) : 45-49.
Kumar A.,Pandey S. C.,Samant M. .2018 .Slow pace of antileishmanial drug development. Parasitology Open, 4(e4) : 1-11.
Madha M.,Haddad S.,Khazem M. .2020 .Evaluation of the effect of Peganum harmala extracts on the in vitro viability of Leishmania tropica promastigotes in comparison to Glucantime. Journal of Parasitic Diseases, 44(4) : 858-863.
Mahmoudvand H.,Kheirandish F.,Mirbadie S. R.,Kayedi M. H.,Ghasemi T.,Bamorovat A. A.,Sharifi M.,I. M. .2017 .The Potential use of methotrexate in the treatment of cutaneous leishmaniasis: In vitro assays against sensitive and meglumine antimoniate-resistant strains of Leishmania tropica. Iranian Journa of Parasitology, 12(3) : 339-347.
Mann S.,Frasca K.,Scherrer S.,Henao-Martínez A. F.,Newman S.,Ramanan P.,Suarez J. A. .2021 .A review of leishmaniasis: current knowledge and future directions. Current Tropical Medicine Report, 8(2) : 121-132.
Masne T.,Kumar D.,Bansode D. .2024 .A review of leishmaniasis: Current knowledge and future directions of heterocyclic molecules. Exploration of Drug Science, 508 : 539.
Srisuton P.,Phumee A.,Sunantaraporn S.,Sor-Suwan R.,S. R.,Pengsakul N.,Siriyasatien T.,P. T. .2019 .Detection of Leishmania and Trypanosoma DNA in Field-Caught sand flies from endemic and non-Endemic areas of leishmaniasis in Southern Thailand. , 10(8) : 238.
Sundar S.,Olliaro P. L. .2007 .Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. Therapeutic and Clinical Risk Management, 3(5) : 733-740.
Torres-Guerrero E.,Quintanilla-Cedillo M. R.,Ruiz-Esmenjaud J.,Arenas R. .2017 .Leishmaniasis: a review. F1000Research, 6 : 750.
Ware J. M.,'Connell O,Brown E. M.,Wetzler L.,Talaat K. R.,Nutman T. B.,Nash T. E. .2021 .Efficacy and tolerability of miltefosine in the treatment of cutaneous leishmaniasis. Clinical Infectious Disseases, 73(7) : e2457-e2562.
World Health Organization. .2023 .Leishmaniasis Fact Sheet. , : .
Zghair K. H. .2017 .In Vitro Assessment of miltefosine activity against promastigotes and axenic amastigotes of Leishmania tropica. Iraqi Journal Science, 22 : 30.
0

Citations

0

Downloads

7

Views